April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer

Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

April 17, 2017 Bio/Pharma/CRO

Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A

Basel, 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children with haemophilia A and inhibitors to factor VIII Results build upon data for emicizumab in adults and adolescents with haemophilia A and inhibitors to factor VIII... Read more

April 10, 2017 Bio/Pharma/CRO PR/Corporate

Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer

Basel, 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared... Read more

April 3, 2017 Clinical Research/Diagn. Product Launch

Roche launches cobas Liat PCR System with four assays into CE-markets

Media Release Basel, 03 April 2017 Roche launches cobas Liat PCR System with four assays into CE-markets First 20 minute real-time PCR nucleic acid test to detect Clostridium difficile, which supports time-sensitive diagnoses in hospitals, urgent care settings and physician offices Infections with Clostridium difficile can quickly become life threatening to high-risk patients cobas Liat... Read more